News


Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has entered into a partnership with CARB-X, under which Melinta will be awarded up to $6.2 million to support the development of the company‚Äôs investigational pyrrolocytosine compounds.